List view / Grid view
A group of researchers, led by Professor Zucai Suo, have revealed the mode of action of two HIV drugs and identified how resistance can develop, which they say could lead to improved drug design in the future.
Here, the benefits of collaborating in drug discovery are explored through the strategic alliance between ELRIG and the British Pharmacological Society.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.
Recent research into why autoimmune disorders affect women four times more frequently than men has revealed several novel therapeutic targets that may lead to the development of future treatments.
Oncologic stem cells have been identified in many malignancies, and targeting these cells could help in the fight against cancer. Here are five of the most recent findings regarding cancer stem cells.
Modern day oncology therapies have seen significant innovation in the last decade. It is high time we commit to using biomarkers that are driven by rational design and the latest computational methods.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
It is said that, on average, it takes a new drug 12 years to go from research lab to patient, with many thousands of candidates discarded along the way. Can artificial intelligence (AI) help to speed things up? Sheraz Gul and Alp Sahin provide an overview of an AI approach…
Humanised immune system (HIS) models have enabled numerous in vivo evaluations of immuno-modulating biologic drugs and ongoing improvements continue to extend their utility. Paul Volden explores the application of HIS models in precision and personalised medicine with a focus on biologics, including how HIS models are used, why they are…
Chemical crosslinking coupled with mass spectrometry (XL-MS) has been used for many years to study protein structure and function. However, recent advances in MS technology, as well as crosslinking reagents and data analysis tools, mean the technique has truly come of age. Here, Albert JR Heck, Alexander Makarov, Henning Urlaub…
The heterogenous and dynamic nature of protein aggregates makes them a particularly challenging class of structures to study. In this article, Professor Tuomas Knowles and Dr Sean Devenish present a novel approach to studying protein structures that could aid in understanding the complexities of Alzheimer’s disease and identify future therapeutic…
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
